A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.

A study by the Mildred Scheel Early Career Center group led by Dr. Mohamed Elgendy at the TUD Faculty of Medicine provides fundamental insights into cancer biology.

Cancer drug resistance is the devastating reason that treatments fail and cancers metastasize, spreading to distant sites ...

This review synthesizes preclinical evidence showing that cinnamon-derived compounds can modulate inflammation, oxidative ...

A tissue section from a mouse model of lung metastasis showing cancer cells (green) that have attracted and activated fibroblasts (red) to support the growth of a metastatic tumor. Image: Massagué Lab ...

In vitro studies pinpoint signaling pathways that could be potential targets in oral squamous cell carcinoma treatments.

Gastric (stomach) cancer remains one of the most common and deadly cancers in East Asia, including Korea. Yet despite its ...

A combination of two supplements — resveratrol and copper — reduced the aggressiveness of tumors in glioblastoma, a type of ...

Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways. Preclinical studies have shown that CLK/DYRK ...

Interrupting one function of a protein that plays a key role in cell signaling could enable the development of new cancer treatments, according to a study led by Dr. Martin Taylor at the Warren Alpert ...